IP Library Granted Patent US 11,268,120
Granted Patent B2
US 11,268,120 · App. 15/625,784 · Granted Mar 8, 2022

Identification of transglutaminase substrates and uses therefor

Inventors: Thomas Albert (Verona, WI); Frank Bergmann (Iffeldorf, DE); Victor Lyamichev (Madison, WI); Jigar Patel (Verona, WI); Michael Schraeml (Penzberg, DE); Wojtek Steffen (Penzberg, DE)
Assignee: Roche Sequencing Solutions, Inc.
C12P21/02C07K1/1075C07K1/13C07K14/00C07K14/4717C12N9/1044C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,268,120
App. No.
15/625,784
Granted
Mar 8, 2022
Kind
B2
Abstract

According to one aspect, the present disclosure provides a method of identifying a substrate of a transglutaminase using a peptide array comprising a plurality of peptides. The method includes the steps of contacting the peptides in the peptide array with the transglutaminase, allowing the transglutaminase to bind to the peptides, and identifying the substrate of the transglutaminase.

Claims (29)

1. A method of cross-linking at least two compounds, the method comprising:

cross-linking a heterologous transglutaminase glutamine substrate peptide present in a first compound with a lysine substrate present in a second compound by contacting the heterologous transglutaminase glutamine substrate peptide and the lysine substrate with a microbial transglutaminase,

wherein:

the heterologous transglutaminase glutamine substrate peptide comprises the sequence motif [YF][VA]LQG and specifically binds the microbial transglutaminase; and

the microbial transglutaminase is a Streptomyces mobaraensis transglutaminase.

2. The method of claim 1 , wherein the heterologous transglutaminase glutamine substrate peptide comprises the sequence motif GDYALQGPG (SEQ ID NO: 79).

3. The method of claim 1 , wherein the lysine substrate is a heterologous transglutaminase lysine substrate peptide, the method further comprising the steps of incorporating the heterologous transglutaminase glutamine substrate peptide into the first compound and the heterologous transglutaminase lysine substrate peptide into the second compound.

4. The method of claim 3 , wherein the heterologous transglutaminase lysine substrate peptide comprises a sequence motif selected from SK[LS]K and [KR][ST]KL.

5. The method of claim 1 , wherein at least one of the first compound and the second compound is a Vitamin D binding protein.

6. The method of claim 3 , wherein the first compound is a Vitamin D binding protein, and wherein the heterologous transglutaminase glutamine substrate peptide comprises the sequence GGGGDYALQGGGG (SEQ ID NO: 85).

7. The method of claim 6 , wherein the second compound comprises a label, and wherein the heterologous transglutaminase lysine substrate peptide is incorporated into the label.

8. The method of claim 7 , wherein the label with the incorporated heterologous transglutaminase lysine substrate peptide is a compound with a formula selected from the group consisting of:

9. A method of cross-linking at least two compounds, the method comprising:

cross-linking a heterologous transglutaminase glutamine substrate peptide present in a first compound with a lysine substrate present in a second compound by contacting the heterologous transglutaminase glutamine substrate peptide and the lysine substrate with a microbial transglutaminase,

wherein:

the heterologous transglutaminase glutamine substrate peptide comprises the sequence motif [YF][VA]LQG and specifically binds the microbial transglutaminase; and

the microbial transglutaminase is a Streptoverticillium sp. transglutaminase.

10. The method of claim 1 , wherein the first compound is a protein comprising an N-terminus and a C-terminus and the heterologous transglutaminase glutamine substrate peptide is attached to the N-terminus or the C-terminus of the protein.

11. The method of claim 1 , wherein the glutamine substrate peptide comprises the sequence motif selected from the group consisting of GGGDYALQGGG (SEQ ID NO:26), CGGDYALQGPG (SEQ ID NO:27), WGGDYALQGPG (SEQ ID NO:28), YGGDYALQGPG (SEQ ID NO:29), DGGDYALQGPG (SEQ ID NO:30), GDGDYALQGPG (SEQ ID NO:31), NGGDYALQGPG (SEQ ID NO:32), GCGDYALQGPG (SEQ ID NO:33), EGGDYALQGPG (SEQ ID NO:34), PGGDYALQGPG (SEQ ID NO:35), TGGDYALQGPG (SEQ ID NO:36), QGGDYALQGPG (SEQ ID NO:37), IGGDYALQGPG (SEQ ID NO:38), FGGDYALQGPG (SEQ ID NO:39), HGGDYALQGPG (SEQ ID NO:40), LGGDYALQGPG (SEQ ID NO:41), VGGDYALQGPG (SEQ ID NO:42), RGGDYALQGPG (SEQ ID NO:43), GWGDYALQGPG (SEQ ID NO:44), MGGDYALQGPG (SEQ ID NO:45), SGGDYALQGPG (SEQ ID NO:46), AGGDYALQGPG (SEQ ID NO:47), GYGDYALQGPG (SEQ ID NO:48), GEGDYALQGPG (SEQ ID NO:49), GPGDYALQGPG (SEQ ID NO:50), GHGDYALQGPG (SEQ ID NO:51), WDGDYALQGGG (SEQ ID NO:52), GGGGDYALQGGGG (SEQ ID NO: 85), GGGDYALQGGGG (SEQ ID NO: 86), and GNGDYALQGPG (SEQ ID NO: 53), and a combination thereof.

12. The method of claim 11 , wherein the lysine substrate comprises a sequence motif selected from the group consisting of ARSKL (SEQ ID NO:54), KSKLA (SEQ ID NO:55), TKSKL (SEQ ID NO:56), KLSKL (SEQ ID NO:57), RSKLG (SEQ ID NO:58), RGSKL (SEQ ID NO:59), RGTKL (SEQ ID NO:60), FPKLK (SEQ ID NO:61), RSKSK (SEQ ID NO:62), SKSKL (SEQ ID NO:63), FTKSK (SEQ ID NO:64), KLKYK (SEQ ID NO:65), PKTKL (SEQ ID NO:66), RLKSK (SEQ ID NO:67), RSKLA (SEQ ID NO:68), GRSKL (SEQ ID NO:69), RAKYK (SEQ ID NO:70), SKLSK (SEQ ID NO:71), KLGAK (SEQ ID NO:72), QRSKL (SEQ ID NO:73), KTKYK (SEQ ID NO:74), LSKLK (SEQ ID NO:75), NRTKL (SEQ ID NO:76), QRTKL (SEQ ID NO:77), GGGRSKLAGGG (SEQ ID NO: 82), GGGARSKLGGGG (SEQ ID NO: 80), and GYKLK (SEQ ID NO:78), and a combination thereof.

13. The method of claim 1 , wherein the lysine substrate comprises a sequence motif selected from the group consisting of ARSKL (SEQ ID NO:54), KSKLA (SEQ ID NO:55), TKSKL (SEQ ID NO:56), KLSKL (SEQ ID NO:57), RSKLG (SEQ ID NO:58), RGSKL (SEQ ID NO:59), RGTKL (SEQ ID NO:60), FPKLK (SEQ ID NO:61), RSKSK (SEQ ID NO:62), SKSKL (SEQ ID NO:63), FTKSK (SEQ ID NO:64), KLKYK (SEQ ID NO:65), PKTKL (SEQ ID NO:66), RLKSK (SEQ ID NO:67), RSKLA (SEQ ID NO:68), GRSKL (SEQ ID NO:69), RAKYK (SEQ ID NO:70), SKLSK (SEQ ID NO:71), KLGAK (SEQ ID NO:72), QRSKL (SEQ ID NO:73), KTKYK (SEQ ID NO:74), LSKLK (SEQ ID NO:75), NRTKL (SEQ ID NO:76), QRTKL (SEQ ID NO:77), GGGRSKLAGGG (SEQ ID NO: 82), GGGARSKLGGGG (SEQ ID NO: 80), and GYKLK (SEQ ID NO:78), and a combination thereof.

14. A method of cross-linking at least two compounds, the method comprising the steps of:

cross-linking a heterologous transglutaminase glutamine substrate peptide present in a first compound with a lysine substrate present in a second compound,

wherein:

the cross-linking comprises allowing the heterologous transglutaminase glutamine substrate peptide and the lysine substrate to come in contact with the microbial transglutaminase whereby the microbial transglutaminase catalyzes the formation of an isopeptide bond between a γ-carboxamide group of a glutamine residue in the sequence motif [YF][VA]LQG and an ε-amino group of a lysine residue in the lysine substrate; and

the microbial transglutaminase is a Streptomyces mobaraensis transglutaminase.

15. The method of claim 14 , wherein the heterologous transglutaminase glutamine substrate peptide comprises the sequence motif selected from the group consisting of GGGDYALQGGG (SEQ ID NO:26), CGGDYALQGPG (SEQ ID NO:27), WGGDYALQGPG (SEQ ID NO:28), YGGDYALQGPG (SEQ ID NO:29), DGGDYALQGPG (SEQ ID NO:30), GDGDYALQGPG (SEQ ID NO:31), NGGDYALQGPG (SEQ ID NO:32), GCGDYALQGPG (SEQ ID NO:33), EGGDYALQGPG (SEQ ID NO:34), PGGDYALQGPG (SEQ ID NO:35), TGGDYALQGPG (SEQ ID NO:36), QGGDYALQGPG (SEQ ID NO:37), IGGDYALQGPG (SEQ ID NO:38), FGGDYALQGPG (SEQ ID NO:39), HGGDYALQGPG (SEQ ID NO:40), LGGDYALQGPG (SEQ ID NO:41), VGGDYALQGPG (SEQ ID NO:42), RGGDYALQGPG (SEQ ID NO:43), GWGDYALQGPG (SEQ ID NO:44), MGGDYALQGPG (SEQ ID NO:45), SGGDYALQGPG (SEQ ID NO:46), AGGDYALQGPG (SEQ ID NO:47), GYGDYALQGPG (SEQ ID NO:48), GEGDYALQGPG (SEQ ID NO:49), GPGDYALQGPG (SEQ ID NO:50), GHGDYALQGPG (SEQ ID NO:51), WDGDYALQGGG (SEQ ID NO:52), GGGGDYALQGGGG (SEQ ID NO: 85), GGGDYALQGGGG (SEQ ID NO: 86), and GNGDYALQGPG (SEQ ID NO: 53), and a combination thereof.

16. The method of claim 15 , wherein the lysine substrate comprises a sequence motif selected from the group consisting of ARSKL (SEQ ID NO:54), KSKLA (SEQ ID NO:55), TKSKL (SEQ ID NO:56), KLSKL (SEQ ID NO:57), RSKLG (SEQ ID NO:58), RGSKL (SEQ ID NO:59), RGTKL (SEQ ID NO:60), FPKLK (SEQ ID NO:61), RSKSK (SEQ ID NO:62), SKSKL (SEQ ID NO:63), FTKSK (SEQ ID NO:64), KLKYK (SEQ ID NO:65), PKTKL (SEQ ID NO:66), RLKSK (SEQ ID NO:67), RSKLA (SEQ ID NO:68), GRSKL (SEQ ID NO:69), RAKYK (SEQ ID NO:70), SKLSK (SEQ ID NO:71), KLGAK (SEQ ID NO:72), QRSKL (SEQ ID NO:73), KTKYK (SEQ ID NO:74), LSKLK (SEQ ID NO:75), NRTKL (SEQ ID NO:76), QRTKL (SEQ ID NO:77), GGGRSKLAGGG (SEQ ID NO: 82), GGGARSKLGGGG (SEQ ID NO: 80), and GYKLK (SEQ ID NO:78), and a combination thereof.

17. The method of claim 14 , wherein the lysine substrate comprises a sequence motif selected from the group consisting of ARSKL (SEQ ID NO:54), KSKLA (SEQ ID NO:55), TKSKL (SEQ ID NO:56), KLSKL (SEQ ID NO:57), RSKLG (SEQ ID NO:58), RGSKL (SEQ ID NO:59), RGTKL (SEQ ID NO:60), FPKLK (SEQ ID NO:61), RSKSK (SEQ ID NO:62), SKSKL (SEQ ID NO:63), FTKSK (SEQ ID NO:64), KLKYK (SEQ ID NO:65), PKTKL (SEQ ID NO:66), RLKSK (SEQ ID NO:67), RSKLA (SEQ ID NO:68), GRSKL (SEQ ID NO:69), RAKYK (SEQ ID NO:70), SKLSK (SEQ ID NO:71), KLGAK (SEQ ID NO:72), QRSKL (SEQ ID NO:73), KTKYK (SEQ ID NO:74), LSKLK (SEQ ID NO:75), NRTKL (SEQ ID NO:76), QRTKL (SEQ ID NO:77), GGGRSKLAGGG (SEQ ID NO: 82), GGGARSKLGGGG (SEQ ID NO: 80), and GYKLK (SEQ ID NO:78), and a combination thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2022
From: BERGMANN, FRANK; SCHRAEML, MICHAEL; STEFFEN, WOJTEK
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 058700/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2022
From: ALBERT, THOMAS; LYAMICHEV, VICTOR; PATEL, JIGAR
To: ROCHE NIMBLEGEN INC.
Reel/Frame 058700/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2022
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE NIMBLEGEN, INC.
Reel/Frame 058700/0347 →
CHANGE OF NAME Recorded Jan 19, 2022
From: ROCHE NIMBLEGEN, INC.
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 058775/0396 →
Continuity (3)
Continuation PCTEP2015079689 · Dec 15, 2015
Provisional Application 62094495 · Dec 19, 2014
Related Publication 20170314054A1 · Nov 2, 2017